Audrea buys BSX 16.92: TheStreet cut Boston Scientific from a buy rating to a hold rating in a research note on Tuesday, August 11th.

Stifel Nicolaus upped their target price on Boston Scientific from $19.00 to $20.00 and gave the stock a buy rating in a report on Friday, July 24th. Several other brokerages also recently commented on BSX. Equities analysts expect that Boston Scientific will post $0.91 EPS for the current fiscal year. The business earned $1.84 billion during the quarter, compared to the consensus estimate of $1.83 billion. Abele bought 100,000 shares of the stock in a transaction dated Monday, August 17th.


Denisha:
These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials and impact of data, product performance and impact and competitive offerings.

Nereida:
The SYNERGY Stent received CE Mark in 2012. View or download an image of the SYNERGY Stent.

Kathline:
Information is also available for those outside the U.S.

Emerita:
Obtain more information on the SYNERGY Clinical Program and Research in the U.S.

Christine:
It features ultrathin stent struts with an abluminal bioabsorbable drug/polymer coating technology that is absorbed shortly after drug elution is complete at three months, thereby eliminating long-term polymer exposure.

Luisa:
About the SYNERGY Bioabsorbable Polymer Stent The SYNERGY Stent is the only bioabsorbable polymer stent available to patients in the U.S.

Vita:
The SYNERGY Stent is designed for faster and sustained healing by eliminating long term polymer exposure.

Antonette:
Long-term exposure to the polymer may cause inflammation, which delays healing and has been associated with complications, including neoatherosclerosis and stent thrombosis.

Tifany:
Existing DES devices reduce coronary restenosis, but the polymer remains on the stent after the drug is delivered.

Shela:
It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.

Boston Scientific Corp. (NYSE:BSX)
//stockhand.net/us/?q=nyse%3Absx&id=721282